SubHero Banner
Text

Fluarix® Quadrivalent (influenza vaccine) – Expanded indication

January 11, 2018 - GlaxoSmithKline announced the FDA approval of Fluarix Quadrivalent (influenza vaccine) for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine in persons aged 6 months and older.

Download PDF